The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FDA asks Tiziana for more information on next 'foralumab' trial

Wed, 01st May 2019 10:08

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.The AIM-traded firm said that, following the end of its 30 calendar day review, the FDA had requested more information and safety data from the ongoing phase 1 trial with nasal administration of foralumab to justify the proposed dose-range for the trial with oral administration of enteric-coated capsules.It said the stability data on the dose-range of 10mg to 250mg of foralumab was included in the submitted IND for the ongoing phase 1 trial with nasal administration.The FDA also advised the company to adequately cross-reference the submitted IND with nasal administration.As a result, Tiziana said it had withdrawn the current IND to include safety data from the ongoing trial with nasal administration, and adequately cross-reference the IND for nasal administration with solution of foralumab.The ongoing phase 1 trial with nasal administration had now completed the first two doses of 10mg and 50mg, with the highest dose of 250mg currently ongoing, which was expected to be completed by 15 May.Upon completion, the firm said the safety data from that ongoing phase 1 trial with nasal administration would be provided to the FDA as part of its revised IND for oral administration."We are in agreement and believe that FDA recommendations will further strengthen our IND for evaluation of oral enteric-coated capsules of foralumab in healthy volunteers," said Tiziana Life Sciences chief executive officer and chief scientific officer Dr Kunwar Shailubhai.As at 0842 BST, shares in Tiziana Life Sciences were down 5.74% at 57.5p.
More News
3 Aug 2020 18:22

UK TRADING UPDATE SUMMARY: Tiziana Offering to Raise GBP57 Million

UK TRADING UPDATE SUMMARY: Tiziana Offering to Raise GBP57 Million

Read more
3 Aug 2020 06:56

IN BRIEF: Tiziana Submits Covid-19 Patent Application For Foralumab

IN BRIEF: Tiziana Submits Covid-19 Patent Application For Foralumab

Read more
20 Jul 2020 21:33

IN BRIEF: Tiziana Bolsters Board By Adding John Brancaccio

IN BRIEF: Tiziana Bolsters Board By Adding John Brancaccio

Read more
16 Jul 2020 13:57

UK TRADING UPDATE SUMMARY: LoopUp Set To Beat Expectations For 2020

UK TRADING UPDATE SUMMARY: LoopUp Set To Beat Expectations For 2020

Read more
9 Jul 2020 16:16

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Jul 2020 21:28

IN BRIEF: Tiziana Life Sciences Progressing On StemPrintER Demerger

IN BRIEF: Tiziana Life Sciences Progressing On StemPrintER Demerger

Read more
29 Jun 2020 20:07

IN BRIEF: Tiziana Seals Manufacturing Agreement With STC Biologics

IN BRIEF: Tiziana Seals Manufacturing Agreement With STC Biologics

Read more
19 Jun 2020 11:06

UK WINNERS & LOSERS SUMMARY: TomCo Shares Double As It Cancels Placing

UK WINNERS & LOSERS SUMMARY: TomCo Shares Double As It Cancels Placing

Read more
19 Jun 2020 10:53

Tiziana Granted US Patent For Oral Administration Of Foralumab

Tiziana Granted US Patent For Oral Administration Of Foralumab

Read more
18 Jun 2020 18:30

IN BRIEF: Tiziana Life Sciences Director Gregor MacRae To Step Down

IN BRIEF: Tiziana Life Sciences Director Gregor MacRae To Step Down

Read more
18 Jun 2020 13:50

Tiziana Annual Loss Widens On Higher Costs, Outlines Busy 2020

Tiziana Annual Loss Widens On Higher Costs, Outlines Busy 2020

Read more
12 Jun 2020 09:39

Tiziana extends ADS sales agreement with ThinkEquity

(Sharecast News) - Tiziana Life Sciences announced an extension to the current 'at the market sales agreement' with ThinkEquity, a division of Fordham Financial Management, on Friday.

Read more
29 May 2020 15:02

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

Read more
29 Apr 2020 16:04

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
27 Apr 2020 14:27

Tiziana Life Sciences Files Patent For Coronavirus Treatment

Tiziana Life Sciences Files Patent For Coronavirus Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.